Durata Therapeutics to Present at JMP Securities Healthcare Conference
CHICAGO, July 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX)
announced today that Paul R. Edick, CEO, will present an overview of the
Company at the 8th Annual JMP Securities Healthcare Conference on Wednesday,
July 10, 2013 at 3:00 PM ET at the St. Regis Hotel in New York City.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.
Any statements in this press release about Durata's future expectations, plans
and prospects constitute forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995, as amended. Actual results
may differ materially from those indicated by such forward-looking statements.
Durata anticipates that subsequent events and developments will cause its
views to change. However, while Durata may elect to update these
forward-looking statements at some point in the future, Durata specifically
disclaims any obligation to do so.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs
Durata Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.